100 related articles for article (PubMed ID: 12054549)
1. Comparison of anti-p53 antibodies in immunoblotting.
Turpeinen M; Serpi R; Rahkolin M; Vähäkangas K
Biochem Biophys Res Commun; 2002 May; 293(2):850-6. PubMed ID: 12054549
[TBL] [Abstract][Full Text] [Related]
2. Differences in epitope accessibility of p53 monoclonal antibodies suggest at least three conformations or states of protein binding of p53 protein in human tumor cell lines.
Danks MK; Whipple DO; McPake CR; Lu D; Harris LC
Cell Death Differ; 1998 Aug; 5(8):678-86. PubMed ID: 10200523
[TBL] [Abstract][Full Text] [Related]
3. Nucleotide sequence of the porcine p53 cDNA, and the detection of recombinant porcine p53 expressed in vitro with a variety of anti-p53 antibodies.
Burr PD; Argyle DJ; Reid SW; Nasir L
Oncogene; 1999 Sep; 18(35):5005-9. PubMed ID: 10490836
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody to a DNA-binding domain of p53 mimics charge structure of DNA: anti-idiotypes to the anti-p53 antibody are anti-DNA.
Herkel J; Kam N; Erez N; Mimran A; Heifetz A; Eisenstein M; Rotter V; Cohen IR
Eur J Immunol; 2004 Dec; 34(12):3623-32. PubMed ID: 15495163
[TBL] [Abstract][Full Text] [Related]
5. Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells.
Legros Y; Lacabanne V; d'Agay MF; Larsen CJ; Pla M; Soussi T
Bull Cancer; 1993 Feb; 80(2):102-10. PubMed ID: 7513565
[TBL] [Abstract][Full Text] [Related]
6. Epitope analysis of the murine p53 tumour suppressor protein.
Lane DP; Stephen CW; Midgley CA; Sparks A; Hupp TR; Daniels DA; Greaves R; Reid A; Vojtesek B; Picksley SM
Oncogene; 1996 Jun; 12(11):2461-6. PubMed ID: 8649788
[TBL] [Abstract][Full Text] [Related]
7. New monoclonal antibodies recognizing p53 protein phosphorylated by casein kinase II at serine 392.
Pospísilová S; Kanková K; Svitáková M; Nenutil R; Vojtesek B
Folia Biol (Praha); 2001; 47(4):148-51. PubMed ID: 11508859
[No Abstract] [Full Text] [Related]
8. The 'wildtype' conformation of p53: epitope mapping using hybrid proteins.
Wang PL; Sait F; Winter G
Oncogene; 2001 Apr; 20(18):2318-24. PubMed ID: 11402327
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies.
Bártek J; Bártková J; Lukás J; Stasková Z; Vojtĕsek B; Lane DP
J Pathol; 1993 Jan; 169(1):27-34. PubMed ID: 8433213
[TBL] [Abstract][Full Text] [Related]
10. Epitope analysis of the human p53 tumour suppressor protein.
Dolezalová H; Vojtĕsek B; Kovarík J
Folia Biol (Praha); 1997; 43(1):49-51. PubMed ID: 9158951
[TBL] [Abstract][Full Text] [Related]
11. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein.
Legros Y; Meyer A; Ory K; Soussi T
Oncogene; 1994 Dec; 9(12):3689-94. PubMed ID: 7526318
[TBL] [Abstract][Full Text] [Related]
12. The effect of phosphorylation on the antigenic reactivity of p53 in cultured human keratinocytes.
Kumar M; Spandau DF
Biochem Biophys Res Commun; 1995 Sep; 214(2):744-53. PubMed ID: 7545906
[TBL] [Abstract][Full Text] [Related]
13. Variation in antigenic determinants of p53 transformation-related protein obtained from various species.
Rotter V; Friedman H; Katz A; Zerivitz K; Wolf D
J Immunol; 1983 Jul; 131(1):329-33. PubMed ID: 6190914
[TBL] [Abstract][Full Text] [Related]
14. Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen.
Lauwen MM; Zwaveling S; de Quartel L; Ferreira Mota SC; Grashorn JA; Melief CJ; van der Burg SH; Offringa R
Cancer Res; 2008 Feb; 68(3):893-900. PubMed ID: 18245492
[TBL] [Abstract][Full Text] [Related]
15. A monoclonal antibody against DNA binding helix of p53 protein.
Yolcu E; Sayan BS; Yağci T; Cetin-Atalay R; Soussi T; Yurdusev N; Ozturk M
Oncogene; 2001 Mar; 20(11):1398-401. PubMed ID: 11313883
[TBL] [Abstract][Full Text] [Related]
16. Polyclonal antibody to porcine p53 protein: a new tool for studying the p53 pathway in a porcine model.
Qiu Y; Shen Y; Li X; Liu Q; Ma Z
Biochem Biophys Res Commun; 2008 Dec; 377(1):151-5. PubMed ID: 18840405
[TBL] [Abstract][Full Text] [Related]
17. Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope.
Baratin M; Kayibanda M; Ziol M; Romieu R; Briand JP; Guiller JG; Viguier M
J Pept Sci; 2002 Jul; 8(7):327-34. PubMed ID: 12148782
[TBL] [Abstract][Full Text] [Related]
18. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
[TBL] [Abstract][Full Text] [Related]
19. Rapid characterization of binding specificity and cross-reactivity of antibodies using recombinant human protein arrays.
Kijanka G; Ipcho S; Baars S; Chen H; Hadley K; Beveridge A; Gould E; Murphy D
J Immunol Methods; 2009 Jan; 340(2):132-7. PubMed ID: 18996391
[TBL] [Abstract][Full Text] [Related]
20. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.
Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR
Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
